Project Details
Description
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
| Status | Active |
|---|---|
| Effective start/end date | 7/5/23 → 7/31/33 |
Funding
- TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.